Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA strand breakage refers to the disruption of the phosphodiester backbone of DNA, resulting in either single-strand breaks (SSBs) or double-strand breaks (DSBs). These lesions are critical forms of DNA damage that can arise from both endogenous cellular processes and exogenous sources. Unrepaired or misrepaired strand breaks can lead to mutations, chromosomal translocations, cell cycle arrest, or apoptosis. Double-strand breaks, in particular, pose significant threats to genomic stability. Cells have evolved robust repair mechanisms, including SSBR, BER, NER, HR, and NHEJ, to address these lesions.
Various; depends on the specific drug and repair pathway involved. Chemotherapeutic agents directly induce DNA strand breaks or interfere with DNA replication, leading to strand breaks. PARP inhibitors prevent the repair of single-strand breaks, leading to double-strand breaks and cell death.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Strand Breakage.